Innovent Biologics has officially announced the launch of its brand-new ESG website, which is designed to showcase the company’s commitment to sustainable development, corporate responsibility, and ethical business practices. In essence, this translates to Innovent’s comprehensive progress and notable achievements in governance, spreading good health, high-quality assurance, employee empowerment, and ecological stewardship. Talk about the whole value proposition on a slightly deeper level, we must expand upon the governance aspect by mentioning how the new website provides you with a transparent view of Innovent’s corporate governance structure, ethical business conduct, compliance with regulations, efficient business operations, and robust risk management practices. Next up, it educates the visitors on company’s work when it comes to innovative drug development. Here, the focus is on Innovent’s strong portfolios in oncology and general biomedicine, as well as its global pipeline of more than 36 innovative assets. You see, thus far, Innovent has successfully launched 10 innovative products, 5 of which have been included in the National Reimbursement Drug List (NRDL), benefiting more than 2.5 million patients. Not just that, the company also makes a point to preach inclusive healthcare and fulfill social responsibilities through comprehensive patient assistance programs that are all, under some capacity, aimed at improving medicine accessibility and affordability.
Another detail that this new website will put on full display is Innovent’s stance on quality, a stance which packs together one robust quality management system which is capable of meeting global standards throughout products’ life cycles. The detail also involves 140,000 liters worth of production capacity, specifically designed to ensure that products meet high-quality standards on a consistent basis. Beyond products, though, Innovent quality commitments are evident in its operational efficiency and a sustainable supply chain.
: “As a world-class biopharmaceutical company, Innovent is committed to integrating ESG principles into our business practices. The launch of our ESG website emphasizes our commitment to transparency, accountability and sustainability. It details our efforts to uphold transparent and responsible governance, build a strong portfolio of oncology and general biomedicine assets, maintain high quality throughout our supply chain, support our employees, and integrate ecological and sustainable practices. We believe that by prioritizing these key ESG areas, we can create long-term value for our stakeholders while contributing to a more sustainable future,” said Dr. Michael Yu, Founder, Chairman and CEO of Innovent Biologics.
Moving on, the platform will further deliver at your disposal an insight into Innovent’s efforts to spearhead green development. These efforts include, for instance, optimizing its environmental management system and securing ISO14001 certification for all production sites. To build upon that, back in 2023, the company also implemented extensive environmental production programs, set climate targets, and established strategies to address climate change proactively.
Among other examples of Innovent’s stature, we must also acknowledge the fact that it boasts, at the moment, an ESG rating of ‘A’ from Morgan Stanley Capital International (MSCI), placing it among the leaders in the biotechnology industry.
